<DOC>
	<DOCNO>NCT02609815</DOCNO>
	<brief_summary>The purpose study investigate gut microbiota change glucose lower effect initial combination therapy gemigliptin metformin compare glimepiride metformin obese patient type 2 diabetes .</brief_summary>
	<brief_title>Initial Combination Gemigliptin Metformin Microbiota Change</brief_title>
	<detailed_description>Obese type 2 diabetes patient treat anti-diabetic medication within 6 week , randomly assign gemigliptin/metformin sulphonylurea/metformin . After 24 week treatment , gut microbiota composition change , glucose lower effect , body weight , gut hormone compare two group .</detailed_description>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes Drug naive ( antidiabetic medication within 6 week ) HbA1c &gt; = 7.5 % BMI &gt; = 25.0 kg/m2 Type 1 diabetes DKA , HHS history hypersensitivity sulphonylurea , metformin DPP4 inhibitor Gestational diabetes mellitus Serum Cr &gt; 1.5 mg/dL ( male ) , &gt; 1.4mg/dL ( female ) Abnormal liver function test Antiobesity medication within 3 month Gastrointestinal motility drug , laxatives within 3 month History major gastrointestinal surgery</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>